Suppr超能文献

利用实验设计优化热熔挤出控释丸剂的配方。

Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.

机构信息

Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, University, MS, USA.

出版信息

J Pharm Pharmacol. 2014 Feb;66(2):309-22. doi: 10.1111/jphp.12129. Epub 2013 Aug 20.

Abstract

OBJECTIVE

The objective of this study was to develop techniques for an abuse-deterrent (AD) platform utilizing the hot-melt extrusion (HME) process.

METHODS

Formulation optimization was accomplished by utilizing Box-Behnken design of experiments to determine the effect of the three formulation factors: PolyOx WSR301, Benecel K15M and Carbopol 71G; each of which was studied at three levels on tamper-resistant (TR) attributes of the produced melt extruded pellets. A response surface methodology was utilized to identify the optimized formulation. Lidocaine hydrochloride was used as a model drug, and suitable formulation ingredients were employed as carrier matrices and processing aids.

KEY FINDINGS

All of the formulations were evaluated for the TR attributes, such as particle size post-milling, gelling and percentage of drug extraction in water and alcohol. All of the design of experiments formulations demonstrated sufficient hardness and elasticity, and could not be reduced into fine particles (<150 μm), which is a desirable feature to prevent snorting. In addition, all of the formulations exhibited good gelling tendency in water with minimal extraction of drug in the aqueous medium. Moreover, Benecel K15M, in combination with PolyOx WSR301, could be utilized to produce pellets with TR potential.

CONCLUSION

HME has been demonstrated to be a viable technique with a potential to develop novel AD formulations.

摘要

目的

本研究旨在开发利用热熔挤出(HME)工艺的滥用防御(AD)平台技术。

方法

通过Box-Behnken 实验设计来完成配方优化,以确定三种配方因素(聚氧化烯 WSR301、羟丙甲纤维素 K15M 和卡波姆 71G)对所制热熔挤出丸剂的抗破坏(TR)特性的影响,每个因素都研究了三个水平。利用响应面法来确定优化的配方。盐酸利多卡因被用作模型药物,合适的配方成分被用作载体基质和加工助剂。

主要发现

所有的配方都进行了 TR 属性的评估,如研磨后的粒径、胶凝和水及酒精中药物的提取百分比。所有实验设计的配方都表现出足够的硬度和弹性,不能被粉碎成细颗粒(<150μm),这是防止吸食的理想特征。此外,所有的配方在水中都表现出良好的胶凝倾向,在水性介质中药物的提取量很少。此外,羟丙甲纤维素 K15M 与聚氧化烯 WSR301 结合使用,可以生产出具有 TR 潜力的丸剂。

结论

HME 已被证明是一种可行的技术,具有开发新型 AD 制剂的潜力。

相似文献

1
Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments.
J Pharm Pharmacol. 2014 Feb;66(2):309-22. doi: 10.1111/jphp.12129. Epub 2013 Aug 20.
2
Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations.
J Opioid Manag. 2017 Nov/Dec;13(6):473-484. doi: 10.5055/jom.2017.0422.
3
Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating.
AAPS PharmSciTech. 2016 Feb;17(1):68-77. doi: 10.1208/s12249-015-0373-2. Epub 2015 Jul 24.
4
Optimization of hot melt extrusion parameters for sphericity and hardness of polymeric face-cut pellets.
Drug Dev Ind Pharm. 2016 Nov;42(11):1833-41. doi: 10.1080/03639045.2016.1178769. Epub 2016 May 4.
7
Five-Stage Approach for a Systematic Screening and Development of Etravirine Amorphous Solid Dispersions by Hot-Melt Extrusion.
Mol Pharm. 2020 Feb 3;17(2):554-568. doi: 10.1021/acs.molpharmaceut.9b00996. Epub 2020 Jan 23.
9
Production of spherical pellets by a hot-melt extrusion and spheronization process.
Int J Pharm. 2002 Aug 21;242(1-2):87-92. doi: 10.1016/s0378-5173(02)00152-7.
10
Extended release pellets prepared by hot melt extrusion technique for abuse deterrent potential: Category-1 in-vitro evaluation.
Int J Pharm. 2020 Sep 25;587:119624. doi: 10.1016/j.ijpharm.2020.119624. Epub 2020 Jul 10.

引用本文的文献

本文引用的文献

1
Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology.
Pharm Dev Technol. 2013 Feb;18(1):186-95. doi: 10.3109/10837450.2012.693505. Epub 2012 Aug 13.
2
Opioid extended-release tablets with improved tamper-resistant properties.
Expert Opin Drug Deliv. 2012 Aug;9(8):879-91. doi: 10.1517/17425247.2012.698606. Epub 2012 Jun 13.
3
Current approaches in tamper-resistant and abuse-deterrent formulations.
Drug Dev Ind Pharm. 2013 May;39(5):611-24. doi: 10.3109/03639045.2012.680468. Epub 2012 Apr 26.
4
Melt extrusion: process to product.
Expert Opin Drug Deliv. 2012 Jan;9(1):105-25. doi: 10.1517/17425247.2012.642365. Epub 2011 Dec 6.
6
Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
Pain Med. 2009 Jul;10 Suppl 2:S124-33. doi: 10.1111/j.1526-4637.2009.00672.x.
7
Patterns of abuse among unintentional pharmaceutical overdose fatalities.
JAMA. 2008 Dec 10;300(22):2613-20. doi: 10.1001/jama.2008.802.
8
Applications of hot-melt extrusion for drug delivery.
Expert Opin Drug Deliv. 2008 Dec;5(12):1357-76. doi: 10.1517/17425240802583421.
10
Pharmaceutical applications of hot-melt extrusion: Part II.
Drug Dev Ind Pharm. 2007 Oct;33(10):1043-57. doi: 10.1080/03639040701525627.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验